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Objectives:  This study  was  designed  to  identify  the  optimal  dose  of  an  MF59®-adjuvanted,  monovalent,
A/H1N1  inﬂuenza  vaccine  in healthy  paediatric  subjects.
Methods:  Subjects  aged  3–8  years  (n =  194)  and  9–17  years  (n =  160)  were  randomized  to receive  two
primary  doses  of  A/H1N1  vaccine  containing  either  3.75  g antigen  with  half  a standard  dose  of  MF59
adjuvant,  7.5  g antigen  with  a full  dose  of MF59,  or  (children  3–8  years  only),  a  non-adjuvanted  15 g for-
mulation.  A  booster  dose  of  MF59-adjuvanted  seasonal  inﬂuenza  vaccine  including  homologous  A/H1N1
strain was  given  one  year  after  priming.  Immunogenicity  was  assessed  by  haemagglutination  inhibition
(HI)  and microneutralization  assays.  Vaccine  safety  was  assessed  throughout  the  study  (up  to  18  months).
Results: A single  priming  dose  of  either  MF59-adjuvanted  formulation  was sufﬁcient  to  meet  the  Euro-
pean  licensure  criteria  for  pandemic  inﬂuenza  vaccines  (HI  titres  ≥1:40  > 70%;  seroconversion  >  40%;  and
GMR  >  2.5).  Two  non-adjuvanted  vaccine  doses  were  required  to meet the  same  licensure  criteria.  After
ﬁrst and  second  doses,  percentage  of  subjects  with  HI titres  ≥1:40  were  between  97% and  100%  in  the
adjuvanted  vaccine  groups  compared  with  68%  and  91%  in  the  non-adjuvanted  group,  respectively.  Post-
vaccination  seroconversion  rates  ranged  from  91% to 98%  in adjuvanted  groups  and  were  68% (ﬁrst  dose)
and  98%  (second  dose)  in  the  non-adjuvanted  group.  HI  titres  ≥1:330  after  primary  doses  were  achieved
in  69%  to 90%  in  adjuvanted  groups  compared  with  41% in  the  non-adjuvanted  group.  Long-term  antibody
persistence  after  priming  and  a robust  antibody  response  to booster  immunization  were  observed  in all
vaccination  groups.  All  A/H1N1  vaccine  formulations  were  generally  well  tolerated.  No  vaccine-related
serious  adverse  events  occurred,  and  no subjects  were  withdrawn  from  the  study  due  to  an  adverse  event.
Conclusions:  An  MF59-adjuvanted  inﬂuenza  vaccine  containing  3.75  g of  A/H1N1  antigen  was  well  tol-
erated  and  sufﬁciently  immunogenic  to  meet  all  the European  licensure  criteria  after  a  single dose  in
healthy  children  3–17 years  old.
©  2014  Elsevier  Ltd.  All  rights  reserved.. IntroductionPandemic outbreaks of inﬂuenza can occur when an inﬂuenza
irus emerges containing haemagglutinin of a novel subtype to
∗ Corresponding author. Tel.:+39 0577 245273; fax: +39 0577 245420.
E-mail address: maria.lattanzi@novartis.com (M.  Lattanzi).
ttp://dx.doi.org/10.1016/j.vaccine.2014.10.085
264-410X/© 2014 Elsevier Ltd. All rights reserved.which the human population has little or no existing immunity.
In June 2009, the World Health Organization (WHO) declared an
inﬂuenza pandemic following the rapid spread of a novel, reassor-
tant, A/H1N1 inﬂuenza virus of swine origin [1].According to the last update released by the WHO  on August
6, 2010 (when the 2009 pandemic was  ofﬁcially declared as
terminated), laboratory-conﬁrmed cases of A/H1N1 inﬂuenza dis-
ease in humans had been reported in more than 214 countries
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orldwide, resulting in over 18,400 fatalities [2]. More recent data
as estimated the number of deaths from the 2009 A/H1N1 pan-
emic at more than 284,000, approximately 15 times the number of
aboratory-conﬁrmed cases [3]. Children were particularly suscep-
ible to A/H1N1 disease, due to relatively higher levels of exposure
ithin communities [4–7]. In the United States, more than 45% of
ospitalizations due to A/H1N1 occurred in children under eighteen
ears of age [6].
Safe and effective A/H1N1 pandemic vaccines providing long-
erm immunity were urgently needed in large quantities to protect
he particularly susceptible paediatric population, and to reduce
evels of transmission within communities [8]. Ideally, pandemic
nﬂuenza vaccines should require a minimal quantity of anti-
en per dose in order to ensure the widest possible population
overage given a limited global capacity for vaccine production.
revious experience with candidate avian (A/H5N1) inﬂuenza pre-
andemic vaccines has shown that the addition of oil-in-water
djuvants, such as MF59® (Novartis Vaccines), allows for a signiﬁ-
ant reduction in antigen content per dose and increased levels of
mmunogenicity [9–11].
A good safety proﬁle for MF59-adjuvanted seasonal and pan-
emic inﬂuenza vaccines has been established [12–15]. The
gg-derived monovalent, MF59-adjuvanted, pandemic vaccine
ocetria® (Novartis Vaccines) was approved for use by the Euro-
ean Medicines Agency with an antigen content of 7.5 g per dose
16]. In a previous study it was demonstrated that a single dose
f this vaccine was sufﬁcient to meet the European Committee for
edicinal Products for Human Use (CHMP) licensure criteria for
andemic inﬂuenza vaccines in adults and elderly [17].
In this study we aimed to identify priming antigen and adjuvant
oses resulting in optimal antibody levels shortly after primary
mmunization in pediatric subjects 3–17 years of age. In addi-
ion, long-term antibody persistence and responses to a one-year
ooster dose were evaluated. Vaccine safety was  assessed up to 18
onths after vaccination.
. Materials and methods
This multinational, single-blind, randomized, dose-range study
as conducted between September 2009 and July 2011 across 11
tudy sites in Germany, 2 sites in Belgium, 1 site in The Netherlands,
 sites in The Dominican Republic, and 2 sites in Chile. One
erman site was excluded from analyses due to noncompliance
ith the protocol requirements for safety reporting for a different
tudy. The trial was performed in accordance with Good Clinical
ractice guidelines and the Declaration of Helsinki. The protocol
as reviewed and approved by the Ethics Committee of each par-
icipating institution. Written informed consent was obtained from
he parent or legal guardian of each subject before enrolment in the
tudy, and, where applicable according to local requirement, assent
as obtained from the subject.
.1. Subjects
A total of 684 healthy children 6 months to 17 years of age
ere included in this clinical study, of which 354 children in one
f the age cohorts 3–8 years and 9–17 years are presented here.
he results of the younger age cohorts (6–11 months and 12–35
onths) will be reported separately.
Main exclusion criteria included any serious illness; hypersensi-ivity or previous adverse reaction to vaccination; inﬂuenza disease,
r previous receipt of any adjuvanted inﬂuenza vaccine, investiga-
ional agent or blood/plasma derivate within three months prior to
nrolment, and an impaired immune function.3 (2015) 174–181 175
2.2. Study procedures
Subjects were divided into 3–8 and 9–17 year-old cohorts. Sub-
jects in the 3–8 year-old age group were randomized in a 2:2:1
ratio to receive vaccine containing either 3.75 g antigen with half
(4.875 mg  squalene) the standard dose of MF59 adjuvant (3.75-Half
MF59), 7.5 g antigen with a standard/full dose (9.75 mg  squalene)
of MF59 (7.5-Full MF59), or a non-adjuvanted 15 g formulation
(15-No MF59), respectively. Subjects in the 9–17 year-old age group
were randomized in equal numbers to receive either 3.75-Half
MF59 or 7.5-Full MF59 vaccine. Subjects were randomly assigned to
a vaccination group using ‘Hidden Entry Envelopes’, in which the
vaccine information was contained in a sealed envelope, preven-
ting tampering and reading of the assigned group before the subject
number was provided. The identity of the assigned vaccine formu-
lation was  not revealed to the subject or their parent/legal guardian.
All subjects received two primary vaccine doses with monovalent
A/H1N1 vaccine given three weeks apart in the deltoid muscle
of the non-dominant arm. One year after primary immunization
a booster dose of MF59-adjuvanted trivalent seasonal inﬂuenza
vaccine was  administered to all subjects. Children who had not pre-
viously received seasonal inﬂuenza vaccine and were <9 years-old
at the time of booster administration were given a second dose
of the adjuvanted seasonal vaccine three weeks later, according to
national recommendations.
Blood samples (∼10 mL  per sample) were collected for immuno-
genicity analyses on Day 1 (baseline), Day 22 (three weeks after ﬁrst
primary dose, window period 18–28 days), Day 43 (three weeks
after second primary dose, window period 18–28 days), Day 366
(one year after primary immunization, window period 350–380
days), and Day 387 (three weeks after ﬁrst booster dose, window
period 18–28 days). Immunogenicity following the second seasonal
vaccine dose was not assessed. The safety follow up was up to 6
months after the booster, for an overall duration of 18 months.
2.3. Vaccines
The investigational MF59-adjuvanted, pandemic subunit vac-
cine (Focetria) contained haemagglutinin and neuraminidase
surface antigens derived from the A/H1N1/California/7/2009
inﬂuenza strain [18]. Each dose of the seasonal, MF59-adjuvanted,
trivalent inﬂuenza subunit vaccine (MF59-TIV), Fluad® (Novartis
Vaccines), contained a standard dose of MF59, and 15 g antigen
from each of the WHO  reference strains recommended for the
2010–2011 inﬂuenza season: A/California/7/2009 (H1N1, homol-
ogous strain); A/Perth/16/2009 (H3N2); and B/Brisbane/60/2008.
Vaccines were supplied in pre-ﬁlled syringes. Single doses of
7.5-Full MF59, 15-No MF59 and of the seasonal vaccines were
administered in a volume of 0.5 mL.  A single dose of the 3.75-Half
MF59 formulation was  administered in a volume of 0.25 mL.
2.4. Immunogenicity assessments
Blood samples were obtained by venipuncture and analysed
using validated methods at the Novartis Serology Laboratory
(Marburg, Germany). Antibody responses against the homologous
A/California/7/2009 (H1N1) strain were assessed by haemagglu-
tination (HI) and MN (microneutralization) assays, as described
previously [19,20]. Antibody responses were expressed as geomet-
ric mean titre (GMTs) at Days 1, 22, 43, 366 and 387, geometric
mean ratio (GMRs) of the postvaccination to prevaccination titres
(Day 22/Day 1; Day 43/Day 1 and Day 387/Day 366), percentage of
subjects with HI titres ≥1:40, HI titres ≥1:330, and seroconversion
rates. Seroconversion was deﬁned as the percentage of subjects per
group achieving at least a 4-fold increase in HI titre from a seropos-
itive prevaccination titre (≥1:10) or a rise from <1:10 to ≥1:40 in
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hose who were originally seronegative. Percentages of subjects
ith HI titres ≥1:330 were also calculated, as this cut-off titre has
een shown to predict an 80% clinical protective level in young chil-
ren, as compared with only 22% protection for the conventional
I titre of ≥1:40 [21].
.5. Safety assessment
Subjects were monitored for 30 minutes after each vaccination
or possible immediate adverse reactions. Parents/legal guardians
ere instructed to complete diary cards to record speciﬁed local
nd systemic reactions for seven days, starting on the day of each
accination [22]. Solicited local reactions were ecchymosis, ery-
hema, induration, swelling, and pain at injection site. Solicited
ystemic reactions included headache, arthralgia, chills, fatigue,
alaise, myalgia, nausea, sweating, and fever (≥38 ◦C, severe
ever ≥40◦). Reports of any unsolicited adverse events (AE) were
ecorded for three weeks after each vaccination. The onset of new
hronic diseases, serious adverse events (SAEs), and AEs leading
o withdrawal were recorded up to 18 months. The investigator
ated AEs as mild, moderate or severe if resulting in no limitation
f, some limitation of, or inability to perform normal daily activities,
espectively.
.6. Statistical analysesSample sizes were chosen to meet or exceed the minimum
equirements of the European guidelines for inﬂuenza vaccine
linical trials. No formal statistical hypothesis was tested, immuno-
enicity endpoints being based on CHMP licensure criteria [23].
Fig. 1. Study design and s3 (2015) 174–181
There are currently no CHMP criteria for vaccinees under 18
years of age, therefore, the following adult licensure criteria
applied: the percentage of subjects achieving seroconversion for
HI antibody should be >40%; the percentage of subjects achiev-
ing HI titre ≥1:40 should be >70% and the GMR  should be >2.5.
Percentages of subjects with HI titres ≥1:330 were also calcu-
lated.
Immunogenicity data reﬂecting the above endpoints, GMTs,
their ratios, and corresponding 2-sided 95% conﬁdence intervals
(CI) were calculated for each vaccine group and age cohort. Safety
data were evaluated descriptively and expressed as the percentage
or number of subjects with AEs in each group.
Immunogenicity analyses were run on the per-protocol (PP) set,
which consisted of subjects who received all the relevant doses of
vaccine correctly, provided at least one evaluable serum sample
at the relevant time points, and had no major protocol violations.
Safety was  analyzed for all subjects exposed to at least one study
vaccination and provided safety data.
3. Results
After exclusion of one study site, 354 subjects were included in
the two  age cohorts 3–8 years (n = 194) and 9–17 years (n = 160).
Across the study groups, 96–100% completed the primary vacci-
nations and 33–65% of study groups completed the study protocol
(Fig. 1). The German Ethical Committee did not allow booster with
adjuvanted TIV. Hence, 21–26% and 54–55% of subjects in age
cohorts 3–8 years and 9–17 years, respectively, were withdrawn
from the study at Day 366. Other reasons for non-study comple-
tion were withdrawal of consent (6–15% across groups), loss to
ubject disposition.
cine 33 (2015) 174–181 177
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Fig. 2. Geometric mean antibody titres (GMTs) against the vaccine strain,
A/H1N1/California/7/2009, measured by HI assay three weeks after ﬁrst (Day 22)M. Knuf et al. / Vac
ollow-up (up to 4% across groups) and protocol deviations (0–1%
cross groups). There were no study withdrawals due to AE.
Vaccine groups were comparable with respect to age, body size
haracteristics, and the majority of study subjects were Caucasian
Table 1). Mean age of the subjects was 5.3 years and 12.4 years
n cohorts 3–8 years and 9–17 years, respectively. The majority
f subjects (68–85%) had not previously been vaccinated against
nﬂuenza.
.1. Immunogenicity
Immunogenicity analyses were performed on the Per Protocol
ata set, which included 80–89% of subjects across groups after
he primary vaccination schedule (Day 43), 27–57% of subjects for
ersistence analyses (Day 366), and 24–50% of subjects for post-
ooster analyses (Day 387).
HI antibody responses to vaccination are summarized in Table 2.
MTs were low at baseline (varying between 7.5 and 13), with
2–24% of subjects across groups having antibody titres ≥1:40. In
oth age cohorts, all subjects in the adjuvanted vaccine groups met
ll three CHMP criteria after the ﬁrst priming dose, and continued to
eet the criteria after receiving the second priming dose. Subjects
ged 3–8 years who received non-adjuvanted vaccine only met  all
hree licensure criteria after the second priming dose.
In subjects aged 3–8 years, geometric mean HI antibody titres
GMTs) increased 34-fold and 37-fold from baseline values after
he ﬁrst priming dose, and increased 88-fold and 81-fold after the
econd vaccine dose in the 3.75-Half MF59 and 7.5-Full MF59 study
roups, respectively (Fig. 2). In this age group, the non-adjuvanted
accine formulation induced a 12-fold increase in HI GMTs after
he ﬁrst priming dose and a 20-fold increase after the second dose.
In subjects aged 9–17 years, corresponding increases in GMTs
ere 43-fold and 67-fold after the ﬁrst priming dose, and 53-fold
nd 90-fold after the second priming dose. In both age groups, sero-
onversion rates in the adjuvanted groups were ≥91% after the ﬁrst
riming dose and ≥92% after the second priming dose. Seroconver-
ion rates in subjects aged 3–8 years who received non-adjuvanted
accine were 68% and 85% after ﬁrst and second doses, respectively.
n both age groups, the proportion of subjects in the adjuvanted
roups achieving HI titres ≥1:40 was ≥97% after the ﬁrst priming
ose and 100% after the second priming dose. In subjects aged 3–8
ears who received non-adjuvanted vaccine, HI titres ≥1:40 were
chieved in 68% after the ﬁrst dose and 91% after the second dose.
Long-term antibody persistence was demonstrated in subjects
eceiving MF59-adjuvanted vaccines; 84–100% of subjects across
ge groups retained HI titres ≥1:40 one year after immunization,
s compared with 63% in those receiving the non-adjuvanted for-
ulation (Table 2). HI GMTs remained 4-fold to 25-fold higher
han baseline values across groups, with the highest antibody
esponses seen in subjects who received the MF59-adjuvanted vac-
ine formulations. All three CHMP licensure criteria were met  by
ll study groups following booster vaccination. HI immunogenic-
ty data were supported by similar MN data (Supplemental Table
). As the study was conducted during and after the pandemic, the
mmunogenicity data could be confounded by previous clinical or
ndiagnosed H1N1 infection. GMTs and percentage of subjects with
I titres ≥1:40 were also assessed by baseline seropositive status.
esults suggest that adjuvanted vaccine formulations are able to
nduce higher immune responses compared to the non-adjuvanted
accine, also in subjects seronegative at baseline (Supplemental
ables 2–3).
Percentages of subjects with HI titres ≥1:330 are presented
n Table 2. In the 3–8 years cohort, more subjects in the adju-
anted groups achieved HI titres ≥1:330 compared with those
eceiving the nonadjuvanted vaccine. HI titres ≥1:330 after pri-
ary vaccinations were achieved in 77–78% of subjects receivingand  second (Day 43) vaccine doses, twelve months after primary immunization
(Day 366), and three weeks after booster administration (Day 387).
adjuvanted formulation and in 41% of subjects receiving the non-
adjuvanted formulation. Following booster, 97–100% (adjuvanted
priming formulations) and 86% (nonadjuvanted priming formula-
tion) of subjects exhibited HI titres ≥1:330. In the 9–17 years cohort,
HI titres ≥1:330 were observed in 69% (3.75-Half MF59) and 90%
(7.5 Full MF59) after primary vaccinations and all subjects (100%)
after the booster dose.
3.2. Safety
All subjects were exposed to at least one study vaccination and
contributed to the safety analyses. In both age groups after both
vaccinations, slightly lower proportions of subjects experienced
solicited reactions following the 3.75-Half MF59 vaccine compared
with the 7.5-Full MF59 formulation. In subjects aged 3–8 years,
rates of solicited reactions were lower with the non-adjuvanted
vaccine formulation than with either of the adjuvanted formula-
tions. In both age groups, rates of solicited reactions were higher
after the booster dose than after either primary dose. In the 3–8
years age group after the second seasonal vaccination, incidence
of solicited reactions decreased. Local and systemic reactions were
typically mild to moderate in severity and of short duration. Few
subjects experienced severe reactions following vaccinations. The
most common local reaction in all study groups was  mild to moder-
ate pain at the site of injection. Fatigue and myalgia were the most
178 M. Knuf et al. / Vaccine 33 (2015) 174–181
Table 1
Study population demographics and baseline characteristics.
3–8 Years
3.75-Half MF59
(n = 77)
3–8 Years
7.5-Full MF59
(n = 78)
3–8 Years
15-No MF59
(n = 39)
9–17 Years
3.75-Half MF59
(n = 80)
9–17 Years
7.5-Full MF59
(n = 80)
Mean age (years, SD) 5.2 ± 1.7 5.4 ± 1.7 5.1 ± 1.7 12.3 ± 2.5 12.4 ± 2.4
Male  subjects (%) 51 56 36 48 49
Mean  weight (kg, SD) 21.8 ± 6.2 21.8 ± 6.3 21.7 ± 6.4 50.9 ± 15.8 51.8 ± 15.9
Mean  height (cm, SD) 114 ± 13 116 ± 11 115 ± 12 156 ± 14 158 ± 15
Mean BMI  (kg/m2, SD) 16.3 ± 1.9 16.0 ± 2.6 16.1 ± 2.4 20.4 ± 4.0 20.3 ± 4.2
Caucasian (%) 68 65 64 93 89
Prior  inﬂuenza vaccination (%) 29 32 15 25 29
SD, standard deviation; BMI, body mass index
Table 2
Immunogenicity analysis (95% CI) by haemagglutination inhibition (HI) assay against A/H1N1/California/7/2009, at baseline (Day 1), three weeks after ﬁrst (Day 22) and
second (Day 43) primary doses, one year after vaccination (Day 366) and three weeks after booster vaccination (Day 387). Bold: CHMP criterion met.
3–8 Years
3.75-Half MF59
(Prime n = 66)
(Boost n = 36)
3–8 Years
7.5-Full MF59
(Prime n = 60)
(Boost n = 37)
3–8 Years
15-No MF59
(Prime n = 34)
(Boost n = 22)
9–17 Years
3.75-Half MF59
(Prime n = 65)
(Boost n = 23)
9–17 Years
7.5-Full MF59
(Prime n = 70)
(Boost n = 23)
Geometric mean titre
Day 1 7.53 (5.08–11) 8.65 (5.67–13) 11 (6.4–17) 13 (8.96–20) 13 (8.81–18)
Day  22 254 (162–399) 322 (199–522) 125 (71–221) 576 (382–869) 868 (579–1301)
Day  43 661 (469–934) 703 (486–1017) 210 (136–324) 710 (541–931) 1174 (899–1533)
Day  366 96 (61–151) (n = 44) 119 (74–191) (n = 43) 55 (31–97) (n = 24) 244 (128–468) (n = 26) 447 (232–858)(n = 27)
Day  387 2616 (1776–3855) 1876 (1311–2685) 1135 (749–1720) 1745 (1142–2666) 1873 (1210–2899)
Geometric mean ratio
Day 22/1 (1st dose) 34 (22–51) 37 (24–58) 12 (7–20) 43 (26–71) 67 (41–108
Day  43/1 (2nd dose) 88 (56–138) 81 (50–132) 20 (11–35) 53 (34–84) 90 (58–142)
Day  387/366 (post-booster) 18 (12–29) 13 (8–19) 17 (10–28) 9.5 (4.6–20) 5.3 (2.5–11)
Seroconversion (%)
Day 22 95 (87–99) 98 (91–100) 68 (49–83) 91(81–97) 96 (88–99)
Day  43 97 (89–100) 98 (91–100) 85 (69–95) 92 (83–97) 94 (86–98)
Day  387 92 (78–98) 95 (82–99) 95 (77–100) 83 (61–95) 61 (39–80)
%  subjects HI titre 1:40
Day 1 12 (5–22) 18 (10–30) 24 (11–41) 14 (7–25) 17 (9–28)
Day  22 97 (89–100) 100 (94–100) 68 (49–83) 97 (89–100) 99 (92–100)
Day  43 100 (95–100) 100 (94–100) 91 (76–98) 100 (94–100) 100 (95–100)
Day  366 84 (70–93) (n = 44) 100 (92–100) (n = 43) 63 (41–81) (n = 24) 96 (80–100) (n = 26) 100 (87–100) (n = 27)
Day  387 100 (90–100) 100 (91–100) 100 (85–100) 100 (85–100) 100 (85–100)
%  subjects HI titre 1:330
Day 1 2 (0.04–8) 0 (0–6) 0 (0–10) 3 (0–11) 3 (0–10)
Day  22 36 (25–49) 33 (22–47) 35 (20–54) 46 (34–59) 66 (53–77)
Day  43 77 (65–87) 78 (66–88) 41 (25–59) 69 (57–180) 90 (80–96)
Day  366 11 (4–25) (n = 44) 7 (1–19) (n = 43) 4 (0–21) (n = 24) 31 (14–52) (n = 26) 41 (22–61) (n = 27)
Day  387 100 (90–100) 97 (86–100) 86 (65–97) 100 (85–100) 100 (85–100)
Table 3
Percentages of 3–8 year-old children experiencing mild to moderate and (severe) solicited local and systemic reactions within one week of vaccine administration.
First dose Second dose MF59-TIV (booster) MF59 TIV (2nd seasonal dose)
3.75-
Half MF59
(n = 78)
7.5-Full
MF59
(n = 77)
15-No
MF59
(n = 39)
3.75-Half
MF59
(n = 77)
7.5-Full
MF59
(n = 75)
15-No
MF59
(n = 38)
3.75-
Half MF59
(n = 48)
7.5-Full
MF59
(n = 52)
15-No
MF59
(n = 25)
3.75-Half
MF59
(n = 28)
7.5-Full
MF59
(n = 30)
15-No
MF59
(n = 14)
Ecchymosis* 9 (0) 10 (0) 10 (0) 5 (0) 3 (0) 5 (0) 6 (0) 10 (0) 12 (0) 0 (0) 7 (0) 0 (0)
Erythema* 21 (0) 26 (0) 13 (0) 27 (0) 20 (0) 11 (0) 35 (2) 29 (0) 24 (0) 32 (0) 30 (0) 7 (0)
Induration* 8 (0) 5 (0) 10 (0) 9 (0) 11 (0) 0 (0) 19 (2) 27 (0) 12 (0) 4 (0) 17 (0) 7 (0)
Swelling* 4 (0) 10 (0) 8 (0) 8 (0) 7 (0) 0 (0) 10 (2) 19 (0) 12 (0) 11 (0) 20 (0) 7 (0)
Pain* 37 (1) 52 (1) 26 (3) 26 (0) 43 (1) 29 (0) 71 (4) 71 (8) 64 (0) 54 (0) 50 (0) 43 (0)
Chills  4 (0) 4 (0) 10 (0) 1 (0) 7 (0) 3 (0) 6 (0) 15 (0) 4 (0) 11 (0) 3 (0) 0 (0)
Malaise 15 (0) 13 (0) 10 (0) 4 (0) 11 (0) 3 (0) 17 (0) 17 (0) 8 (0) 7 (0) 7 (0) 7 (0)
Myalgia 8 (0) 13 (0) 8 (0) 6 (0) 11 (0) 0 (0) 19 (2) 31 (4) 8 (0) 0 (0) 13 (0) 0 (0)
Arthralgia 4 (0) 8 (0) 8 (0) 3 (0) 7 (0) 0 (0) 8 (0) 15 (2) 8 (0) 4 (0) 17 (0) 7 (0)
Headache 9 (0) 19 (0) 3 (0) 5 (0) 13 (0) 5 (0) 8 (0) 29 (2) 16 (0) 7 (0) 20 (0) 0 (0)
Sweating 1 (1) 3 (0) 8 (0) 0 (0) 5 (1) 3 (0) 6 (0) 6 (0) 0 (0) 4 (0) 3 (0) 0 (0)
Fatigue 27 (0) 17 (0) 21 (0) 8 (0) 19 (0) 11 (3) 21 (0) 19 (0) 12 (0) 11 (0) 23 (0) 7 (0)
Nausea 12 (1) 5 (0) 3 (0) 6 (1) 5 (1) 3 (0) 8 (2) 13 (0) 12 (0) 4 (4) 13 (0) 7 (7)
Fever  (≥38 ◦C) 4 (0) 4 (0) 5 (0) 0 (0) 3 (0) 0 (0) 6 (0) 12 (0) 0 (0) 7 (0) 7 (0) 0 (0)
Use  Analgesic/
antipyretic
13 12 13 5 13 5 13 15 16 14 13 7
* Solicited local reaction.
§ Severe fever deﬁned as a body temperature ≥40 ◦C.
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Table  4
Percentages of 9–17 year-old children experiencing mild to moderate and (severe) solicited local and systemic reactions within one week of vaccine administration.
First dose Second dose MF59 TIV (booster)
3.75-Half
MF59
(n = 79)
7.5-Full
MF59
(n = 80)
3.75-Half
MF59
(n = 79)
7.5-Full
MF59
(n = 79)
3.75-Half
MF59
(n = 26)
7.5-Full
MF59
(n = 27)
Ecchymosis* 9 (0) 8 (0) 4 (0) 4 (0) 4 (0) 4 (0)
Erythema* 14 (0) 11 (0) 14 (0) 18 (0) 19 (4) 19 (0)
Induration* 13 (0) 15 (0) 11 (0) 9 (0) 23 (0) 19 (0)
Swelling* 9 (0) 9 (0) 5 (0) 5 (0) 19 (0) 15 (0)
Pain* 53 (0) 60 (1) 43 (1) 52 (1) 85 (4) 81 (15)
Chills  3 (0) 4 (0) 4 (0) 3 (0) 4 (0) 15 (0)
Malaise  10 (0) 13 (1) 9 (1) 6 (0) 27 (0) 15 (0)
Myalgia  15 (1) 21 (0) 9 (0) 10 (0) 38 (0) 41 (4)
Arthralgia 5 (0) 6 (0) 6 (1) 5 (0) 19 (0) 26 (0)
Headache 20 (0) 18 (0) 16 (1) 14 (0) 15 (0) 48 (0)
Sweating 1 (0) 1 (0) 3 (0) 1 (0) 8 (4) 26 (0)
Fatigue  18 (1) 24 (0) 14 (1) 10 (0) 27 (0) 26 (0)
Nausea  4 (0) 5 (1) 6 (0) 10 (0) 15 (0) 19 (0)
Fever  (≥38 ◦C) 3 (0) 3 (0) 3 (0) 1 (0) 4 (0) 4 (0)
Use  Analgesic/antipyretic 5 13 10 9 4 22
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R* Solicited local reaction.
§ Severe fever deﬁned as a body temperature ≥40 ◦C.
ommon reported systemic reactions (Tables 3 and 4). No subjects
xperienced severe fever (≥40 ◦C) at any time during the study.
For spontaneously reported AEs, no differences in overall
requency of AEs were observed between the two  adjuvanted
ormulations and between adjuvanted and nonadjuvanted formu-
ations.
Rates of reported unsolicited AEs were generally low, 34–46%
nd 1–15% of subjects across age and vaccine groups after primary
nd booster vaccinations, respectively.
Between Days 1–366, there were 14 subjects with SAEs (sim-
larly distributed across groups), none of which related to study
accination. There were 9 new onsets of chronic diseases, one of
hich of mild severity was considered at least possibly related
o study vaccination (malabsorption in 9–17 years cohort, 7.5-
ull MF59 group) (Table 5). No premature study withdrawals were
bserved. After the booster vaccination (Days 366 to 546), only 2
ubjects in age cohort 3–8 years experienced an SAE (one case of
sthma in 3.75-Half MF59 group and one case of adenoidal hyper-
rophy in 7.5-Full MF59 group), none of which was  considered
elated to study vaccination. During this period, there were no
nsets of chronic diseases and no subjects were withdrawn due
o an AE.. Discussion
This study was performed to identify which quantities of
riming A/H1N1 antigen and MF59 adjuvant resulted in optimal
able 5
isting of new onset of chronic diseases throughout the study (Day 1 to 366).
Vaccine formulation Preferred term 
3–8 years 3.75-Half MF59 Attention deﬁcit/hyperactivity dis
Rhinitis allergic 
7.5-Full MF59 Urinary tract infection
Seasonal allergy 
Attention deﬁcit/hyperactivity dis
15-No MF59 Attention deﬁcit/hyperactivity dis
9–17  years 3.75-Half MF59 Irritable bowel syndrome 
Polycystic ovaries 
7.5-Full MF59 Scoliosis 
Malabsorption 
esults are presented for individual subjects.
* The event was resolved, but a complication resulted as a consequence of the event.antibody levels after primary and booster inﬂuenza vaccina-
tions in healthy paediatric subjects aged 3–17 years. During any
future inﬂuenza pandemic, the global demand for vaccine would
undoubtedly exceed current manufacturing capacity. Dose-sparing
strategies, such as the use of adjuvants in order to reduce anti-
gen content per dose, are critical to ensure that vaccine supply
is able to meet public demand. This study found all three doses
of A/H1N1 vaccine formulations to be highly immunogenic and
well tolerated in healthy children and adolescents. Enhanced anti-
body titres were observed in response to the MF59-adjuvanted
vaccines compared with the non-adjuvanted formulation after pri-
mary immunization. The MF59-adjuvanted vaccines also resulted
in enhanced long-term antibody persistence and higher antibody
titres following booster administration, with no safety concerns.
Previous experience with pre-pandemic A/H5N1 (avian)
inﬂuenza vaccines suggested that at least two vaccine doses would
be required to induce adequate levels of seroprotection against
novel inﬂuenza strains in naïve populations [20,24–26]. However,
the present study demonstrated that a single dose of A/H1N1
vaccine containing 3.75 g of antigen and half a dose of MF59
was sufﬁcient to meet all the CHMP licensure criteria for pan-
demic inﬂuenza vaccines. Findings of this study are in agreement
with previously published results of MF59-adjuvanted A/H1N1 vac-
cine in adults and children [17,27–30]. Similar results were also
reported in paediatric and adult populations using the AS03®-
adjuvanted H1N1 pandemic vaccine (GlaxoSmithKline Biologicals,
Wavre, Belgium) [31,32], providing further proof of the beneﬁts of
adjuvanted A/H1N1 vaccines.
Onset day Severity Outcome Relatedness
order 201 Moderate AE persistent None
329 Mild AE persistent None
45 Moderate Alive/sequela* None
173 Moderate AE persistent None
order 300 Mild AE persistent None
order 180 Mild AE persistent None
271 Moderate AE persistent None
306 Mild AE persistent None
39 Mild AE persistent None
65 Mild AE persistent Possibly related
1 cine 3
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The HI titre of 1:40, which has been determined as an immuno-
ogic correlate corresponding to a 50% reduction in the risk of
ontracting inﬂuenza, is based on studies in adults and may  not be
eneralizable to children. Indeed, a recent study in a large pediatric
opulation indicated that the conventional HI titre of 1:40 was only
ssociated with 22% protection, whereas titres of 1:110 or 1:330
ould predict a 50% or an 80% clinical protective level [21]. Our
esults demonstrate that in children receiving MF59-adjuvanted
ormulations, a high proportion reached the stringent HI cut-off
itre ≥1:330 postvaccination, i.e. 69–90% and 97–100% after pri-
ary and booster doses, respectively, as compared with 41% in
hildren receiving the non-adjuvanted vaccine. Following booster
accination, 86% of subjects primed with the nonadjuvanted for-
ulation reached the HI cut-off titre ≥1:330, demonstrating the
bility of seasonal MF59 vaccine to boost the immune responses
lso in the subjects who previously received the nonadjuvanted
accine. These ﬁndings provide further support for the use of MF59-
djuvanted vaccines in the pediatric population.
No vaccine-related SAEs were reported during the whole study
uration of approximately 18 months, and no subjects were
ithdrawn due to AEs. These ﬁndings support the good safety pro-
le of MF59-adjuvanted vaccines observed during other studies
10,11,26,33–36] and after the mass A/H1N1 pandemic vaccina-
ions of 2009 [12].
In conclusion, a monovalent A/H1N1 vaccine containing 3.75 g
ntigen and half the standard amount of MF59 per dose was  highly
mmunogenic and well tolerated in healthy paediatric subjects
ged 3–17 years, inducing antibody responses sufﬁcient to meet
ll three CHMP licensure criteria after a single dose.
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